L-Carnitine is a prescription therapy used for fat metabolism and energy production.

Patients seeking support for fat metabolism and energy production may qualify after evaluation by a licensed provider.

Yes. Injectable L-Carnitine (Levocarnitine, 500 mg/mL) is a compounded prescription preparation dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required to confirm clinical suitability and establish the appropriate route, dosing, and frequency.

Injectable L-Carnitine is generally well tolerated at therapeutic doses. Common side effects may include nausea, vomiting, diarrhea, nasal congestion, restlessness, insomnia, and a characteristic fishy body odor resulting from bacterial conversion of carnitine to trimethylamine. Serious but less common side effects requiring prompt medical attention include tachycardia, hypertension, and fever. Patients with a history of seizure disorders should be monitored closely during treatment. Report any unusual or persistent symptoms to your provider.

Patients with known hypersensitivity to levocarnitine or any component of the formulation should not receive this preparation. Those with significant renal impairment require individualized evaluation, as levocarnitine clearance is reduced in this population. Patients with an active seizure disorder, those taking anticonvulsant medications associated with carnitine depletion, or those on pivalate-conjugated antibiotics should disclose these to their provider before starting. Safety in pregnancy and breastfeeding has not been fully established for injectable use.

Two clinically significant interaction categories apply. Pivalate-conjugated antibiotics (such as pivampicillin) form conjugates with carnitine that are excreted in urine, depleting carnitine stores — monitoring is warranted with concurrent use. Certain anticonvulsants including valproic acid, phenobarbital, phenytoin, and carbamazepine are associated with meaningfully reduced blood carnitine levels; valproic acid may also cause hepatotoxicity and elevated plasma ammonia, increasing the complexity of concurrent therapy. Inform your provider and pharmacist of all medications and supplements before starting.

Patients with significant renal impairment require careful dosing adjustments and close monitoring. Those with hepatic conditions, cardiovascular disease, or active seizure disorders should have their complete health history reviewed before initiating therapy. Patients with hypothyroidism should be monitored, as carnitine supplementation may influence thyroid hormone utilization. Your provider will determine the appropriate protocol based on your complete medical history.